Abstract
Carcinoids are malignant neuroendocrine tumors consisting of a spectrum of neoplasms from low-grade typical carcinoid to high-grade small cell carcinoma. We report a case of atypical thymic carcinoid that responded to neoadjuvant therapy with octreotide and sunitinib, an oral multikinase inhibitor. After 3 weeks of treatment, tumor size significantly decreased to allow for a safe surgical resection with clear margins. We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors.
Original language | English (US) |
---|---|
Pages (from-to) | 94-97 |
Number of pages | 4 |
Journal | Journal of Thoracic Oncology |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2008 |
Keywords
- Carcinoids
- Growth factor receptor
- Neoadjuvant therapy
- Octreotide
- Platelet-derived growth factor receptor
- Somatostatin receptor
- Sunitinib
- Vascular endothelial